Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxorubicin hydrochloride, quantity: 50 mg - injection - excipient ingredients: water for injections; dilute hydrochloric acid; sodium chloride - doxorubicin has been successfully used to produce regression in neoplastic conditions, eg acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma, etc. the main antitumour activities are listed in table 1. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - adriamycin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms? tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin?s and non-hodgkin?s type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. adriamycin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder (tis, t1, t2).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin hydrochloride has been used successfully both as a single agent and also in combination with other approved cancer chemotherapeutic agents to produce regression in neoplastic conditions such as: acute lymphoblastic leukaemia, acute myeloblastic leukaemia, wilms? tumour, neuroblastomas, soft tissue sarcomas, bone sarcomas, breast cancer, gynecologic carcinomas, testicular carcinomas, bronchogenic carcinoma, hodgkin?s and non-hodgkin?s lymphoma, thyroid carcinoma, bladder carcinomas, head and neck cancer and gastric cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - doxorubicin hydrochloride, quantity: 50 mg - injection, powder for - excipient ingredients: methyl hydroxybenzoate; lactose - doxorubicin has been used successfully to produce regression in neoplastic conditions such as acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's types, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma. doxorubicin is also indicated by intravesical administration in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2).

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: hydrochloric acid; sodium hydroxide; sucrose; histidine; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; hydrogenated soy phosphatidylcholine; ammonium sulfate; ethanol; water for injections - liposomal doxorubicin sun, as monotherapy, is indicated for the treatment of metastatic breast cancer.,liposomal doxorubicin sun is also indicated for the treatment of:,? advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.,? aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.,liposomal doxorubicin sun may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline).,liposomal doxorubicin sun is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: water for injections; cholesterol; ethanol; hydrogenated soy phosphatidylcholine; ammonium sulfate; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; histidine; hydrochloric acid; sodium hydroxide; sucrose - liposomal doxorubicin sun, as monotherapy, is indicated for the treatment of metastatic breast cancer.,liposomal doxorubicin sun is also indicated for the treatment of:,? advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.,? aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.,liposomal doxorubicin sun may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). liposomal doxorubicin sun is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxorubicin hydrochloride, quantity: 200 mg - injection - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - doxorubicin has been successfully used to produce regression in neoplastic conditions, eg acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma, etc. the main antitumour activities are listed in table 1. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxorubicin hydrochloride, quantity: 100 mg - injection - excipient ingredients: water for injections; dilute hydrochloric acid; sodium chloride - doxorubicin has been successfully used to produce regression in neoplastic conditions, eg acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma, etc. the main antitumour activities are listed in table 1. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.